

Application No. 10/517,509
Information Disclosure Statement dated November 2, 2005
Attorney Docket No. 0470-045922

IFW
1614



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Application No. : 10/517,509
Applicant : Herman Jan Tijmen COELINGH BENNINK et al.
Filed : June 13, 2005
Title : METHOD OF TREATING HUMAN SKIN AND A SKIN
CARE COMPOSITION FOR USE IN SUCH A METHOD
Group Art Unit : 1614
Examiner : Not Yet Assigned
Confirmation No. : 1291
Customer No. : 28289

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the requirements of 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby submit this Information Disclosure Statement, which includes a completed Form PTO/SB/08A and one (1) copy of each reference identified thereon.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 2, 2005.	
Lisa R. McNany (Name of Person Mailing Document)	
 Signature	11/2/2005 Date


This application is the United States national phase of PCT Application No. PCT/NL03/00420, filed June 11, 2003, claiming priority to European Application No. 02077273.7, filed June 11, 2002. This Information Disclosure Statement lists the prior art references identified in the International Search Report (ISR) for the PCT application and the references are relevant for the reasons stated therein. Further United States Patent No. 5,063,507 from page 13 of the present application is also identified. The July 14, 2004 Notice of Acceptance of Application Under 35 U.S.C. §371 and 37 C.F.R. §1.495, indicates that the ISR and the International Preliminary Examination Report (IPER) were received by the United States Patent and Trademark Office. However, copies of the ISR and IPER are included herewith for the Examiner's convenience.

In the IPER, the International Preliminary Examination Authority has indicated that claims 1-16 are novel, have an inventive step, and have industrial applicability. As the claims of the present application are identical to the PCT claims, it is believed that the presently claimed invention is patentable over the cited prior art and that the claims are in condition for allowance.

Since this Information Disclosure Statement is being submitted before the mailing date of a first Office Action on the merits, it is timely under 37 C.F.R. §1.97(b)(3) and no fee is required. The Commissioner for Patents is hereby authorized to charge any additional fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.

Respectfully submitted,

THE WEBB LAW FIRM

By 

William H. Logsdon
Registration No. 22,132
Attorney for Applicant
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: 412-471-8815
Facsimile: 412-471-4094

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/517,509
Filing Date	June 13, 2005
First Named Inventor	Herman Jan Tijmen Coelingh Bennink
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	0470-045922

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ² Number ³ Kind Code ⁴ (if known)				
	2	WO 03/018026	03-06-2003	Pan-Tarhei Bioscience B.V.		
	3	WO 00/63762	10-26-2000	Imapharm GmbH & Co	Abstract only	

Examiner Signature	/Samira Jean-Louis/	Date Completed	03/14/2008
-----------------------	---------------------	-------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation/registration number (optional). ² See Kinda codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Patent Office that issued the document, by the patent class code (WIPAC Standard 5-3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 97 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and) by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 114. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. There will be no charge to the individual for this collection. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

{W0226387.1}

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SJL/



PTO/SB/08b (07/05)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/517,509
Filing Date	June 13, 2005
First Named Inventor	Herman Jan Tijmen Coelingh Bennink
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	0470-045922

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	MUECK et al., "Angio and Anti-Angiogenic Effects of Estradiol and its Metabolites", J. Clin. Basic Cardiol., 2001, pp. 153-155, Vol. 4, No. 2.	
	5	SHAH et al., "Estrogen and Skin. An Overview", Am. J. Clin. Dermatol., 2001, pp. 143-150, Vol. 2, No. 3.	
	6	SITRUK-WARE et al., "Local Hormonal Treatment for Urogenital Atrophy After Menopause", Schweiz. Rundsch, Med. Praxis, 1997, pp. 1245-1248, Vol. 86, No. 33.	
	7	SCHMIDT et al., "Treatment of Skin Aging with Topical Estrogens", Int. J. Dermatol., 1996, pp. 669-674, Vol. 35, No. 9.	

Examiner Signature	/Samira Jean-Louis/	Date Considered	03/14/2008
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

{W0226387.1}

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SJL/